The pharmaceutical sector has never been in the limelight in such a conjoined, simultaneous, worldwide capacity before. Coronavirus has posed a whole new problem; the industry is at a halt in terms of developing a vaccine and must mobilize faster than ever before, despite specific constraints and hurdles. The industry's capacity to explain the changes, difficulties, and possibilities it presents in different languages is almost as challenging as developing a vaccine. However, because the supply chain had been disrupted, the supply of essential healthcare products began to dwindle at an alarming rate. As a result of the emergence of COVID-19, this industry has become one of the busiest sectors in the world.
Title : Resveratrol derivatives a new tool for osteogenic induction in the treatment of peri implantitis
Barbara De Filippis, University “G. d’Annunzio, Italy
Title : Non-coding RNAs in the cardiovascular disorders linked to Chronic Kidney Disease
Laurent Metzinger, University of Picardie Jules Verne, France
Title : Drugs as an environmental problem chromatographic and computational studies of drugs partition between soil and water
Anna Weronika Sobanska, Medical University of Lodz, Poland
Title : miR-29b inhibition in triple negative cells target apoptosis and autophagy related mechanisms
Cornelia Braicu, Iuliu Haţieganu University of Medicine and Pharmacy, Romania
Title : Synthesis and in vitro study of antiproliferative heterocyclic scaffolds
Hitendra M Patel, Sardar Patel University, India
Title : Mucoadhesive microcapsule: A novel approach for controlling & sustained drug delivery!
Subas Chandra Dinda, Teerthanker Mahaveer University, India